Skip to main content
QXL Diagnostics
Lab Science & NABL Verified Clinical Guide

Autoimmune Encephalitis & Paraneoplastic Antibody Panels: How Paired CSF & Serum Testing Detects Treatable Neurological Disorders in Bangalore

Clinically Reviewed by Dr. Pritilata Rout, MD (Histopathology & Clinical Pathology)Head of Biochemistry · QXL Diagnostics (NABL Lab MC-6849)
November 16, 2026
8 min read
12 Sections
Autoimmune Encephalitis & Paraneoplastic Antibody Panels: How Paired CSF & Serum Testing Detects Treatable Neurological Disorders in Bangalore - QXL Diagnostics Bengaluru
Share Clinical Guide:
When psychiatric symptoms or unexplained seizures are actually an autoimmune attack on the brain. An alumna of NIMHANS explains autoimmune encephalitis vs paraneoplastic neurological syndromes, why paired CSF and serum testing is non-negotiable, and how cell-based immunofluorescence identifies reversible neurological conditions.

Quick answer: Autoimmune neurological disorders occur when the immune system mistakenly targets proteins in the central nervous system. These conditions fall into two fundamentally distinct diagnostic and therapeutic categories:

  1. Autoimmune Encephalitis (Cell-Surface Antibodies): Targets extracellular receptor proteins on the outside of living neurons (e.g., Anti-NMDAR, LGI1, CASPR2, AMPAR1/2, GABA-B R1/R2). Because these antibodies cause reversible receptor internalization without destroying the underlying neuron, patients frequently make dramatic, complete recoveries when treated early with immunotherapy (steroids, IVIG, plasma exchange, rituximab).
  2. Paraneoplastic Neurological Syndromes (Intracellular Onconeural Antibodies): Targets intracellular nuclear or cytoplasmic antigens (e.g., Anti-Hu, Anti-Yo, Anti-Ri, Amphiphysin, CV2/CRMP5, PNMA2/Ma2). These antibodies serve as immunological red flags for an underlying hidden cancer (small cell lung cancer, ovarian teratoma, breast carcinoma, thymoma) that may not yet be visible on routine imaging.

Mandatory Paired Testing: Modern neuroimmunology guidelines emphasize that both cerebrospinal fluid (CSF) and venous serum must be tested simultaneously. For Anti-NMDAR encephalitis, CSF sensitivity is near 100%, whereas serum can be falsely negative in up to 15% of confirmed cases. Conversely, Anti-LGI1 antibodies are sometimes more readily detectable in serum. [1–3]

Medically reviewed by: Dr. Pritilata Rout, MD (Pathology), Senior Consultant Pathologist & NIMHANS Alumna, QXL Diagnostics Central Reference Laboratory, Bengaluru.
Published: 16 November 2026 · Reading time: approximately 15 minutes.
Diagnostic Turnaround: 3 to 5 Days · Multiplex Cell-Based Indirect Immunofluorescence (CBA & Line Blot).


Cell-Surface vs Onconeural Antibodies: Fundamental Differences#

Diagnostic FeatureAutoimmune Encephalitis PanelParaneoplastic Neurologic Panel
Antigen LocationOuter cell surface (synaptic receptors / ion channels)Intracellular (nuclear or cytoplasmic proteins)
Key Target AntibodiesNMDAR, LGI1, CASPR2, AMPAR1/2, GABA-B R1/R2Hu (ANNA-1), Yo (PCA-1), Ri (ANNA-2), Amphiphysin, CV2, PNMA2
Typical Patient DemographicsYoung adults, adolescents, pediatric patients (especially NMDAR)Older adults (>50 years), long-term smokers (Hu, CV2)
Common Clinical PresentationAcute behavioral change, psychosis, seizures, memory loss, dystoniaSubacute cerebellar ataxia, sensory neuronopathy, limbic encephalitis
Association with CancerVariable (NMDAR ~40% ovarian teratoma; LGI1 rarely cancer)Extremely high (>85% associated with occult malignancy)
Mechanism of Neuronal DamageReversible antibody-mediated receptor crosslinking / internalizationIrreversible cytotoxic T-cell-mediated neuronal destruction
Response to ImmunotherapyExcellent (often dramatic recovery if treated early)Limited (requires surgical removal and treatment of underlying tumor)
Specimen RequirementPaired CSF & Serum MandatorySerum generally adequate; paired CSF preferred
QXL Test Price in Bangalore₹23,275 (MRP ₹24,500)₹8,075 (MRP ₹8,500)

When Should Clinicians Suspect Autoimmune Encephalitis?#

Autoimmune encephalitis frequently presents with symptoms that masquerade as psychiatric breakdown, viral meningitis, or idiopathic epilepsy. Diagnostic testing is indicated when a patient develops subacute symptoms (progressing over less than 3 months) involving:

  1. Subacute Psychiatric Breakdown: Rapid-onset acute psychosis, auditory or visual hallucinations, severe paranoia, and personality change in a young patient with no prior psychiatric history.
  2. Faciobrachial Dystonic Seizures (FBDS): Pathognomonic for Anti-LGI1 encephalitis—brief (under 3 seconds), frequent (dozens to hundreds of times daily) involuntary jerking movements involving the arm and the ipsilateral face. Recognizing FBDS allows curative immunotherapy before irreversible hippocampal damage and memory loss occur.
  3. New-Onset Refractory Status Epilepticus (NORSE): Severe continuous seizures unresponsive to standard dual antiepileptic medications.
  4. Movement Disorders & Autonomic Instability: Oromandibular dyskinesias (tongue protrusion, lip-smacking, chewing movements), catatonia, cardiac dysrhythmias, hypoventilation, and extreme temperature fluctuations (classic in Anti-NMDAR encephalitis).
  5. Persistent Unexplained Hyponatremia: Low blood sodium levels accompanying cognitive decline strongly point toward LGI1-mediated syndrome of inappropriate antidiuresis.

Why Paired CSF and Serum Testing is Mandatory#

A frequent error in clinical diagnostics is submitting only a blood serum sample to save on hospital procedural costs. Modern neuroimmunology demonstrates why this practice risks catastrophic misdiagnosis:

  • Intrathecal Antibody Synthesis: In Anti-NMDAR encephalitis, the antibody is synthesized directly within the central nervous system by B cells crossing the blood-brain barrier. In published clinical series, up to 15% of patients with confirmed NMDAR encephalitis had detectable antibodies in CSF while serum was completely negative. Relying on serum alone results in a false-negative report and missed treatment.
  • Serum False Positives: Conversely, weak nonspecific binding in serum can produce false-positive antibody bands on immunoblot assays. Finding matching antibodies in CSF confirms genuine intrathecal pathology.
  • Accompanying CSF Biomarkers: A lumbar puncture simultaneously evaluates CSF opening pressure, lymphocytic pleocytosis (elevated WBCs in fluid), elevated CSF protein (>45 mg/dL), and oligoclonal bands (OCBs), corroborating neuroinflammation.

Paraneoplastic Onconeural Antibodies: Finding the Hidden Tumor#

When an onconeural antibody on the paraneoplastic panel tests positive, it acts as a molecular beacon directing oncological staging:

  • Anti-Hu (ANNA-1): Strongly predicts Small Cell Lung Cancer (SCLC) in >85% of cases; typically presents as painful sensory neuronopathy or autonomic neuropathy.
  • Anti-Yo (PCA-1): Strongly associated with Ovarian, Fallopian Tube, or Breast Carcinomas; presents as subacute progressive cerebellar ataxia (inability to walk, slurred speech).
  • Anti-Ri (ANNA-2): Associated with breast cancer or SCLC; causes opsoclonus-myoclonus (dancing eyes, dancing feet) and brainstem encephalitis.
  • Anti-Ma2 / PNMA2: Highly specific for Testicular Germ Cell Tumors in young men or non-small cell lung cancer in older adults; causes severe limbic and brainstem dysfunction.
  • Anti-CV2 / CRMP5: Suggests SCLC or thymoma; causes chorea, optic neuropathy, and mixed polyneuropathy.

If an onconeural antibody is identified, whole-body FDG PET-CT scanning, pelvic/scrotal ultrasound, and mammography should be performed immediately, and repeated at 3 to 6-month intervals if initial imaging is negative, as the tumor may take months to reach visible size.


Specimen Collection & Laboratory Methodology#

  • Autoimmune Encephalitis Panel: Requires paired collection—CSF (minimum 2 mL in sterile polypropylene container) collected via lumbar puncture by a clinical neurologist, and Venous Blood (3 mL in red-top plain tube without gel) collected simultaneously.
  • Paraneoplastic Panel: Serum (3 mL plain tube) or paired CSF/Serum.
  • Methodology: Dual-platform testing utilizing Cell-Based Indirect Immunofluorescence (CBA) with transfected HEK293 cells expressing native receptor conformations, complemented by high-specificity recombinant line immunoblotting.
  • Turnaround Time: 3 to 5 working days at QXL Diagnostics Central Reference Laboratory, Kengeri, Bengaluru.

Frequently Asked Questions (FAQs)#

1. Does the autoimmune encephalitis blood test require fasting?#

No. Neither CSF nor blood testing for autoimmune encephalitis or paraneoplastic antibodies requires fasting. However, lumbar puncture procedures require standard hospital pre-procedural assessment (coagulation screen, platelet count, brain neuroimaging to exclude raised intracranial pressure).

2. Can a patient have autoimmune encephalitis with normal MRI and CT scans?#

Yes. Brain MRI is normal in approximately 30% to 50% of patients with confirmed Anti-NMDAR encephalitis during early presentation. An apparently normal MRI does not rule out autoimmune encephalitis; clinical suspicion, CSF analysis, and antibody testing take precedence.

3. What is the difference between infectious and autoimmune encephalitis?#

Infectious encephalitis is caused by a living microorganism (such as Herpes Simplex Virus 1, Varicella Zoster, or Japanese Encephalitis) directly invading brain tissue, requiring immediate intravenous antivirals (Acyclovir). Autoimmune encephalitis is sterile inflammation driven by host antibodies; treating with high-dose steroids or IVIG without ruling out viral infection can worsen viral encephalitis, which is why viral PCR (HSV PCR) and autoimmune panels are typically sent simultaneously.

4. How much does an autoimmune encephalitis panel cost in Bangalore?#

At QXL Diagnostics, the comprehensive Autoimmune Encephalitis Panel (paired CSF & serum screening for NMDAR, LGI1, CASPR2, AMPAR1/2, and GABA-B) costs ₹23,275 (discounted from ₹24,500 MRP). The Paraneoplastic Neurologic Panel costs ₹8,075 (discounted from ₹8,500 MRP). Both tests report within 3 to 5 days.

5. Can patients fully recover from autoimmune encephalitis?#

Yes. With early diagnosis and prompt administration of first-line immunotherapy (intravenous methylprednisolone, intravenous immunoglobulin, or therapeutic plasma exchange), over 75% to 80% of patients with cell-surface antibody encephalitis achieve substantial or complete functional recovery, returning to school, work, and normal life.


References & Clinical Guidelines#

  1. Graus F, Titulaer MJ, Balu R, et al. A clinical approach to diagnosis of autoimmune encephalitis. Lancet Neurol. 2016;15(4):391–404.
  2. Dalmau J, Graus F. Antibody-mediated encephalitis. N Engl J Med. 2018;378(9):840–851.
  3. Graus F, Vogrig A, Muñiz-Castrillo S, et al. Updated Diagnostic Criteria for Paraneoplastic Neurologic Syndromes. Neurol Neuroimmunol Neuroinflamm. 2021;8(4):e1014.
  4. Lancaster E. The Diagnosis and Treatment of Autoimmune Encephalitis. J Clin Neurol. 2016;12(1):1–13.
  5. ISO 15189:2022 Medical Laboratories — Requirements for quality and competence. NABL Certificate MC-6849.

Medical & Laboratory Disclaimer

This clinical article is published solely for patient education and informational purposes. It does not replace personal medical advice, clinical diagnosis, prenatal genetic counselling, or obstetric supervision. Appropriate laboratory investigations must be determined by your treating physician based on your personal health history.

Medically Reviewed & Fact-Checked Reviewed: November 16, 2026

Dr. Pritilata Rout, MD (Histopathology & Clinical Pathology)

Head of Clinical Biochemistry & Quality Management, QXL Diagnostics Bengaluru (NABL Accredited Laboratory MC-6849). Trained Lead Assessor for ISO 15189:2022 medical laboratory standards.

QXL Clinical Editorial Commitment: Every health guide, biomarker explanation, and screening schedule published on this portal undergoes rigorous clinical review by qualified MD pathologists and biochemists to ensure adherence to peer-reviewed evidence (ACOG, WHO, ICMR) and laboratory diagnostic accuracy.

Share Clinical Guide:

Related Clinical Guides

Explore more evidence-based diagnostic articles and testing guidelines